Variant Summary
- HGVS
- —
- Variant Type(s)
- —
- Evidence Items
- 5
Evidence Level Distribution
Level B: 3Level D: 2
Evidence Items
Showing CIViC evidence rows where gene = MET and variant = Overexpression.
| Level | Type | Direction | Significance | Disease | Drugs | Rating |
|---|---|---|---|---|---|---|
| B | Predictive | Does Not Support | Sensitivity/Response | Stomach Carcinoma | Rilotumumab | 5 |
| B | Predictive | Supports | Resistance | Skin Melanoma | Vemurafenib | 4 |
| B | Predictive | Does Not Support | Resistance | Skin Melanoma | Vemurafenib | 3 |
| D | Predictive | Supports | Resistance | Uveal Melanoma | Trametinib,Selumetinib | 3 |
| D | Predictive | Supports | Sensitivity/Response | Uveal Melanoma | Crizotinib | 1 |